Últimas noticias sobre Third Harmonic Bio (NASDAQ:THRD) Bolsa

Third Harmonic Bio

Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.

Third Harmonic Bio Inc

Third Harmonic Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.29) by 20.69 percent. This is a 75 percent decrease over losses of $(0.20) per share from the same period last year.

Earnings

Earnings Misses

News

THRD

Third Harmonic Bio Q1 EPS $(0.35) Misses $(0.29) Estimate

As of April 15, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Certara Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERT#NASDAQ">CERT</a>)</h3>
<ul>
<li>On April 14, Certara issued a year-over-year increase in its first-quarter revenue guidance and announced a $100 million share repurchase program. Additionally, the company announced it launched a non-animal navigator solution to help drug developers reduce reliance on animal testing. The company's stock jumped around 50% over the past five days and has a 52-week high of $17.94.</li>
<li>RSI Value: 80.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>CERT Price Action: Shares of Certara gained 11.5% to close at $14.40 on Monday.</li>
<li>Edge Stock Ratings: 25.78 Momentum score with Value at 6.21.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/cert"><img loading="lazy" decoding="async" width="476" height="183" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15054617/image-108.png" alt="" class="wp-image-871812" style="width:278px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15054617/image-108.png 476w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15054617/image-108-300x115.png 300w" sizes="(max-width: 476px) 100vw, 476px" /></a></figure>
<h3 class="wp-block-heading">Summit Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>)</h3>
<ul>
<li>On March 26, Citigroup analyst Yigal Nochomovitz upgraded Summit Therapeutics from Neutral to Buy and raised the price target from $23 to $35. The company's stock gained around 45% over the past five days and <a href="https://www.benzinga.com/quote/SMMT">has a 52-week high</a> of $33.89.</li>
<li>RSI Value: 74.6</li>
<li>SMMT Price Action: Shares of Summit Therapeutics gained 12.4% to close at $26.13 on Monday.</li>
</ul>
<h3 class="wp-block-heading">Third Harmonic Bio Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>)</h3>
<ul>
<li>On April 14, Third Harmonic announced that its board approved and adopted a plan for the liquidation and dissolution of the company and the distribution of remaining cash to shareholders, including any proceeds from asset and intellectual property sales. "Our management team and board of directors together have completed an efficient review of our strategic alternatives for maximizing the value of our assets and have determined that returning cash to shareholders and selling our assets, including THB335, is the best path forward," said Natalie Holles, CEO of Third Harmonic Bio. The company's stock gained around 46% over the past month and has a<a href="https://www.benzinga.com/quote/THRD"> 52-week high</a> of $16.94.</li>
<li>RSI Value: 87.7</li>
<li>THRD Price Action: Shares of Third Harmonic Bio gained 39.8% to close at $5.09 on Monday.</li>
</ul>
Curious about other BZ Edge Rankings? Click here to discover <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">how similar stocks measure up</a>. 
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44787747/wall-streets-most-accurate-analysts-spotlight-on-3-consumer-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Consumer Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Short Ideas

Pre-Market Outlook

Markets

CERT

SMMT

Top 3 Health Care Stocks You May Want To Dump This Quarter

<h3>Gainers</h3>
<ul>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) shares moved upwards by 68.6% to $0.04 during Monday's regular session. </li>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) stock rose 54.25% to $0.19. The market value of their outstanding shares is at $5.7 million. </li>
<li>Third Harmonic Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) stock increased by 39.56% to $5.08. The company's market cap stands at $229.1 million. </li>
<li>Metsera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSR#NASDAQ">MTSR</a>) shares increased by 34.27% to $18.8. The market value of their outstanding shares is at $1.9 billion. </li>
<li>Wellgistics Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGRX#NASDAQ">WGRX</a>) stock increased by 31.14% to $3.79. The company's market cap stands at $196.8 million. </li>
<li>I-MAB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMAB#NASDAQ">IMAB</a>) stock increased by 29.1% to $0.86. The company's market cap stands at $69.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Ironwood Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) stock fell 30.0% to $0.66 during Monday's regular session. The market value of their outstanding shares is at $105.9 million. </li>
<li>CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) stock declined by 22.36% to $0.24. The market value of their outstanding shares is at $19.9 million. </li>
<li>Alumis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) shares declined by 21.84% to $5.07. The market value of their outstanding shares is at $275.5 million. </li>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) shares decreased by 17.92% to $0.38. The company's market cap stands at $4.2 million. </li>
<li>Bullfrog AI Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRG#NASDAQ">BFRG</a>) shares declined by 17.62% to $1.73. The company's market cap stands at $16.2 million. </li>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) shares decreased by 17.58% to $0.95. The company's market cap stands at $1.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ALMS

APDN

BFRG

IMAB

IRWD

MTSR

RSLS

STSS

WGRX

Longevity Health Holdings, Inc. - Common Stock

XAGE

12 Health Care Stocks Moving In Monday's Intraday Session

Third Harmonic Bio Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) shares are soaring on Monday after the company announced a <a href="https://www.benzinga.com/pressreleases/25/04/g44784897/third-harmonic-bio-announces-plan-of-liquidation-and-dissolution">plan of liquidation and dissolution</a>.
What Happened: Third Harmonic announced that its board approved and adopted a plan for the liquidation and dissolution of the company and the distribution of remaining cash to shareholders, including any proceeds from asset and intellectual property sales. 
The clinical-stage biopharmaceutical company noted that it plans to complete all Phase 2 readiness for its THB335 program by mid-year to maximize the value of the program before a potential sale. 
Third Harmonic plans to seek shareholder approval of the dissolution plan at its annual meeting on June 5. Pending shareholder authorization, the company plans to file a Certificate of Dissolution with the Secretary of the State of Delaware in the third quarter.
&#8220;Our management team and board of directors together have completed an efficient review of our strategic alternatives for maximizing the value of our assets and have determined that returning cash to shareholders and selling our assets, including THB335, is the best path forward,&#8221; said Natalie Holles, CEO of Third Harmonic Bio. 
&#8220;We are proud of the work that our team has done over the past years to advance our science, to make tough decisions, and to act with integrity in the best interest of our patients and shareholders.&#8221;
Third Harmonic estimated that the total shareholder distribution will be in the range of&nbsp;$246.6 million&nbsp;to&nbsp;$259.8 million, or approximately&nbsp;$5.13&nbsp;to&nbsp;$5.42&nbsp;per share. The estimates do not include potential proceeds from any sales of the company&#8217;s remaining assets and intellectual property.
Third Harmonic Bio shares were up 39%, trading around $5.06 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44787818/sp-500-could-tank-to-4000-if-trump-put-fizzles-says-jpmorgan">S&amp;P 500 Could Tank To 4,000 If &#8216;Trump Put&#8217; Fizzles, Says JPMorgan</a></li>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/04/44787201/third-harmonic-bio-apple-dell-and-other-big-stocks-moving-lower-in-mondays-pre-market-session">Third Harmonic Bio, Apple, Dell And Other Big Stocks Moving Higher In Monday&#8217;s Pre-Market Session</a></li>
</ul>
This illustration was generated using artificial intelligence via Midjourney.

Third Harmonic Bio Stock Is Up 40% Monday: What's Happening?

Editor's Note: The headline has been updated to reflect that the stocks are moving higher.
U.S. stock futures were higher this morning, with the Dow futures gaining around 400 points on Friday.
Shares of Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) rose sharply in today's pre-market trading after the Trump administration announced tariff <a href="https://www.benzinga.com/quote/AAPL">exemptions for smartphones</a>.
Apple shares gained 5.8% to 209.56 in the pre-market trading session.
Here are some other stocks moving higher in pre-market trading.
<ul>
<li>Third Harmonic Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) shares jumped 36.8% to $4.98 in pre-market trading after the company announced a plan of liquidation and dissolution.</li>
<li>Theratechnologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THTX#NASDAQ">THTX</a>) gained 32.5% to $2.57 in pre-market trading. Future Pak, on Friday, proposed to acquire the company for $255 million.</li>
<li>TMC the metals company Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMC#NASDAQ">TMC</a>) gained 20% to $2.34 in pre-market trading following a 5% gain on Friday.</li>
<li>Viking Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) rose 14.5% to $25.45 in pre-market trading after gaining 3% on Friday.</li>
<li>MP Materials Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MP#NYSE">MP</a>) rose 12% to $25.40 in pre-market trading. MP Materials will release its financial results for the first quarter, after the closing bell on Thursday, May 8.</li>
<li>Best Buy Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) gained 8.8% to $65.76 in pre-market trading after the Trump administration excluded a range of technology products, including consumer electronics from the 145% reciprocal tariffs bucket.</li>
<li>Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) climbed 5.8% to $86.73 in pre-market trading &nbsp;after the Trump administration excluded a range of technology products, including consumer electronics from the 145% reciprocal tariffs bucket.</li>
<li>NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) rose 3% to $114.17 in pre-market trading after the Trump administration excluded a range of technology products, including consumer electronics from the 145% reciprocal tariffs bucket.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/04/44759831/top-3-industrials-stocks-that-may-explode-in-april">Top 3 Industrials Stocks That May Explode In April</a> </li>
</ul>
Photo via Shutterstock

Trading Ideas

AAPL

DELL

NVDA

THTX

VKTX

Third Harmonic Bio, Apple, Dell And Other Big Stocks Moving Higher In Monday's Pre-Market Session (CORRECTED)

<h3>Gainers</h3>
<ul>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) stock increased by 76.0% to $0.04 during Monday's pre-market session. </li>
<li>Third Harmonic Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) shares increased by 37.36% to $5.0. The company's market cap stands at $225.5 million. </li>
<li>Verve Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>) shares increased by 32.2% to $4.31. The company's market cap stands at $382.7 million. </li>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) shares moved upwards by 27.6% to $0.16. The market value of their outstanding shares is at $4.7 million. </li>
<li>Artelo Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARTL#NASDAQ">ARTL</a>) shares rose 26.52% to $1.04. The market value of their outstanding shares is at $3.3 million. </li>
<li>Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) stock increased by 22.3% to $0.2. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Gyre Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GYRE#NASDAQ">GYRE</a>) shares declined by 17.4% to $6.21 during Monday's pre-market session. The company's market cap stands at $581.3 million. </li>
<li>Ironwood Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) stock fell 16.45% to $0.79. The market value of their outstanding shares is at $126.4 million. </li>
<li>Virax Biolabs Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAX#NASDAQ">VRAX</a>) shares declined by 14.18% to $0.95. The company's market cap stands at $4.1 million. </li>
<li>Pasithea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTTA#NASDAQ">KTTA</a>) shares decreased by 12.67% to $1.24. The company's market cap stands at $3.3 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) stock declined by 11.7% to $0.26. The company's market cap stands at $1.9 million. </li>
<li>MSP Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSPR#NASDAQ">MSPR</a>) stock declined by 11.61% to $2.21. The company's market cap stands at $4.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARTL

GYRE

KTTA

MSPR

PTIX

VERV

VRAX

12 Health Care Stocks Moving In Monday's Pre-Market Session

AAPL: 6% &#x7C; <a href="https://www.benzinga.com//node/44784872">Apple shares are trading higher after the Trump administration announced tariff exemptions for smartphones.</a>
&nbsp;
THRD: 40% &#x7C; <a href="https://www.benzinga.com//node/44785153">Third Harmonic Bio shares are trading higher after the company announced a plan of liquidation and dissolution.</a>
&nbsp;
SGN: 75% &#x7C; <a href="https://www.benzinga.com//node/44784822">Signing Day Sports To Acquire blockchAIn Digital Infrastructure In $215M All-Stock Deal, Targeting Crypto Mining And AI Expansion</a>

Market-Moving News for April 14th

WIIM

Third Harmonic Bio shares are trading higher after the company announced a plan of liquidation and dissolution.

<ul>
<li>Board of Directors has approved plan to liquidate and intends to seek stockholder approval for dissolution of the Company at the Annual Meeting of Stockholders on June 5, 2025</li>
<li>Initial distribution expected in the range between approximately $246.6 million and $255.4 million, or approximately $5.13 and $5.33 per share of common stock, expected in the third quarter of 2025</li>
<li>Sale of the Company's assets, including THB335, to be initiated pending stockholder approval of the Plan of Liquidation and Dissolution</li>
</ul>

Third Harmonic Bio Announces Plan Of Dissolution With Payout Between $246.6M–$255.4M Pending Stockholder Approval

Stifel analyst Alex Thompson downgrades Third Harmonic Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) from Buy to Hold and lowers the price target from $23 to $5.

Downgrades

Price Target

Analyst Ratings

Stifel Downgrades Third Harmonic Bio to Hold, Lowers Price Target to $5

Third Harmonic Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) reported quarterly losses of $(1.09) per share which beat the analyst consensus estimate of $(1.18) by 7.63 percent. This is a 39.74 percent decrease over losses of $(0.78) per share from the same period last year.

Earnings Beats

Third Harmonic Bio FY 2024 GAAP EPS $(1.09) Beats $(1.18) Estimate

On Tuesday, Third Harmonic Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) revealed results from its Phase 1 single and multiple ascending dose (SAD/MAD) trial of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43618804/third-harmonic-bio-announces-phase-1-clinical-results-for-thb335-and-provides-corporate-strategic-" rel="noreferrer noopener">THB335 in healthy volunteers</a>.
The company says the data are expected to support the advancement of THB335 into a Phase 2 trial in chronic spontaneous urticaria (CSU).
Dose-dependent reductions in serum tryptase, a biomarker of mast cell activation, were observed in the MAD cohorts, with mean reductions from baseline ranging from 13% to 84% at Day 15.
THB335 was generally safe and well tolerated in the SAD cohorts. There were 3 subjects in the MAD cohorts with isolated, transient asymptomatic transaminase elevations. Two of the three subjects received a placebo (1 subject in the 21 mg cohort and 1 subject in the 164 mg cohort), and 1 active subject received THB335 in the 164 mg cohort.
Transaminase elevations in the 164 mg cohort were largely consistent in time course and magnitude for the placebo and active subjects.
The company intends to continue THB335 development activities through the first half of 2025 to prepare for the initiation of a 12-week, placebo-controlled Phase 2 study in CSU by mid-year 2025.
The company also initiated a strategic review process to run in parallel with Phase 2 readiness activities to identify opportunities to maximize shareholder value.
&#8220;As we evaluate the competitive landscape and current market dynamics, we believe the right thing for our stakeholders is to evaluate a full range of strategic transactions and/or business combinations to maximize value creation across all assets in the company&#8230;&#8221; said Natalie Holles, Chief Executive Officer of Third Harmonic Bio.
In conjunction with this announcement, the company is halting all non-THB335 related research and discovery activities and undertaking a reduction in workforce of approximately 50%. As of December 31, 2024, the company had approximately $285 million in cash and cash equivalents.
After accounting for expenses related to THB335 Phase 2 readiness activities, continuing operations, and restructuring costs, Third Harmonic Bio estimates it will have cash and cash equivalents of approximately $262 million to $267 million on June 30, 2025.
In December 2022, Third Harmonic discontinued the Phase 1b study of THB001 in chronic inducible urticaria after observing asymptomatic liver transaminitis in two subjects enrolled in the first dose <a target="_blank" href="https://www.benzinga.com/general/biotech/22/12/30093276/third-harmonic-bio-stock-plummets-after-trial-discontinuation-on-safety-concerns" rel="noreferrer noopener">cohort of 200mg BID</a>.
Price Action: THRD stock closed at $3.56 on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/02/43629559/novartis-to-beef-up-heart-disease-offering-with-3-billion-blackstone-backed-anthos-therapeutics-deal" target="_blank" rel="noreferrer noopener">Novartis To Beef Up Heart Disease Offering With $3 Billion Blackstone-Backed Anthos Therapeutics Deal</a></li>
</ul>

Biotech

Health Care

General

Third Harmonic Bio Initiates Strategic Review, Lays Off 50% Staff Citing Competitive Landscape

Morgan Stanley analyst Michael Ulz downgrades Third Harmonic Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) from Overweight to Equal-Weight and lowers the price target from $20 to $5.

Morgan Stanley Downgrades Third Harmonic Bio to Equal-Weight, Lowers Price Target to $5

<h3>Gainers</h3>
<ul>
<li>Lipella Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIPO#NASDAQ">LIPO</a>) stock moved upwards by 49.5% to $4.56 during Tuesday's pre-market session. The market value of their outstanding shares is at $5.5 million. </li>
<li>IN8bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INAB#NASDAQ">INAB</a>) shares increased by 49.46% to $0.4. The company's market cap stands at $29.2 million. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) stock rose 38.58% to $0.21. The company's market cap stands at $7.1 million. </li>
<li>Firefly Neuroscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIFF#NASDAQ">AIFF</a>) stock rose 38.06% to $4.28. The market value of their outstanding shares is at $34.2 million. </li>
<li>Travere Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVTX#NASDAQ">TVTX</a>) stock rose 16.35% to $24.55. The company's market cap stands at $2.1 billion. </li>
<li>Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) shares increased by 13.06% to $5.54. The company's market cap stands at $118.1 million. As per the press release, Q1 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>T2 Biosystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTOO#NASDAQ">TTOO</a>) shares declined by 43.4% to $0.11 during Tuesday's pre-market session. The market value of their outstanding shares is at $3.0 million. </li>
<li>Third Harmonic Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) shares fell 29.25% to $3.29. The company's market cap stands at $148.2 million. </li>
<li>Aspira Womens Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>) stock declined by 26.7% to $0.26. The company's market cap stands at $4.4 million. </li>
<li>vTv Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTVT#NASDAQ">VTVT</a>) shares declined by 18.97% to $15.0. The market value of their outstanding shares is at $39.1 million. </li>
<li>Lixte Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) stock fell 17.54% to $1.88. The company's market cap stands at $4.2 million. </li>
<li>Hyperfine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYPR#NASDAQ">HYPR</a>) stock decreased by 16.77% to $1.39. The company's market cap stands at $101.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIFF

ENTA

HYPR

INAB

LIPO

LIXT

OCEA

TTOO

TVTX

VTVT

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Third Harmonic Bio shares are trading lower after Raymond James downgraded the stock from Outperform to Market Perform.

Raymond James analyst Laura Prendergast downgrades Third Harmonic Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) from Outperform to Market Perform.

Raymond James Downgrades Third Harmonic Bio to Market Perform

Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times

<ul>
<li>THB335 Phase 1 data support advancement into Phase 2 clinical trial in&nbsp;chronic spontaneous urticaria (CSU)</li>
<li>Company initiating process to leverage balance sheet strength to&nbsp;maximize shareholder value</li>
<li>Cash and cash equivalents of approximately $285 million as of December 31, 2024 (unaudited)</li>
</ul>

Third Harmonic Bio Says Data From Its Phase 1 Trial Of THB335 In Healthy Volunteers Supports The Advancement Into A Phase 2 Trial In Chronic Spontaneous Urticaria; The Company Is Initiating A Strategic Review Process To Run In Parallel With Phase 2 Readiness Activities To Identify Opportunities To Maximize Shareholder Value

<h3>Gainers</h3>
<ul>
<li>Lipella Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIPO#NASDAQ">LIPO</a>) stock moved upwards by 64.9% to $5.03 during Tuesday's pre-market session. The company's market cap stands at $6.0 million. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) stock moved upwards by 50.47% to $0.22. The market value of their outstanding shares is at $7.7 million. </li>
<li>Third Harmonic Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) stock increased by 20.21% to $5.59. The market value of their outstanding shares is at $251.8 million. </li>
<li>Lixte Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) stock increased by 15.78% to $2.64. The company's market cap stands at $5.9 million. </li>
<li>Silexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) shares increased by 15.26% to $1.51. The market value of their outstanding shares is at $6.0 million. </li>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) shares rose 10.53% to $0.11. The company's market cap stands at $6.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Prelude Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRLD#NASDAQ">PRLD</a>) shares fell 17.4% to $0.9 during Tuesday's pre-market session. The market value of their outstanding shares is at $49.5 million. </li>
<li>Stoke Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STOK#NASDAQ">STOK</a>) shares declined by 11.3% to $9.11. The market value of their outstanding shares is at $482.5 million. </li>
<li>DIH Holding US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DHAI#NASDAQ">DHAI</a>) stock decreased by 10.75% to $0.61. The market value of their outstanding shares is at $21.5 million. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) stock declined by 10.62% to $4.8. The market value of their outstanding shares is at $3.2 million. </li>
<li>Invivyd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVVD#NASDAQ">IVVD</a>) shares fell 9.56% to $1.42. The market value of their outstanding shares is at $169.8 million. </li>
<li>Avinger (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGR#NASDAQ">AVGR</a>) stock declined by 9.0% to $0.44. The company's market cap stands at $1.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AVGR

BDRX

CNSP

DHAI

IVVD

PRLD

SLXN

STOK

Trading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News Pending

Press Releases

Third Harmonic Bio to Participate in the Jefferies Global Healthcare Conference

Third Harmonic Bio Announces Second Quarter 2024 Financial Results and Provides Business Update

Third Harmonic Bio to Participate in Upcoming Investor Conferences

Third Harmonic Bio to Participate in Upcoming Investor Conferences in September

Third Harmonic Bio Announces Third Quarter 2024 Financial Results

Third Harmonic Bio to Participate in Upcoming Investor Conferences in November

Third Harmonic Bio to Participate in the 7th Annual Evercore HealthCONx Conference

Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 and Provides Corporate Strategic Update

Third Harmonic Bio Announces Fourth Quarter and Full Year 2024 Financial Results

Comments

Third Harmonic Bio

Noticias

Últimas noticias sobre Third Harmonic Bio (NASDAQ:THRD) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL